NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis $3.19 -0.31 (-8.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.74▼$3.4450-Day Range$1.53▼$4.0052-Week Range$1.35▼$7.92Volume1.27 million shsAverage Volume861,955 shsMarket Capitalization$1.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Salarius Pharmaceuticals alerts: Email Address Salarius Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish10.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($214.40) to ($188.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.38 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Salarius Pharmaceuticals.Read more about Salarius Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.68% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently increased by 215.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSalarius Pharmaceuticals does not currently pay a dividend.Dividend GrowthSalarius Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRX. Previous Next 3.2 News and Social Media Coverage News SentimentSalarius Pharmaceuticals has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Salarius Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest10 people have searched for SLRX on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows1 people have added Salarius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Salarius Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.Read more about Salarius Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Salarius Pharmaceuticals are expected to grow in the coming year, from ($214.40) to ($188.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Salarius Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Salarius Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSalarius Pharmaceuticals has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Salarius Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.Read More SLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRX Stock News HeadlinesJuly 25 at 3:39 PM | benzinga.comWhy Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJuly 23 at 3:07 PM | investorplace.comWhy Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 23 at 3:04 PM | investorplace.comWhy Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?July 19, 2024 | barrons.comSalarius Pharmaceuticals Inc.July 19, 2024 | benzinga.comSalarius Pharmaceuticals (NASDAQ:SLRX) Stock, Short Interest ReportJune 12, 2024 | globenewswire.comSalarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitMay 14, 2024 | investorplace.comSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 2, 2024 | finance.yahoo.comSLRX Pursues Important GoalMarch 27, 2024 | msn.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataMarch 25, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 23, 2024 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | sfgate.comSalarius: Q4 Earnings SnapshotMarch 22, 2024 | globenewswire.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comQuoin stock craters 47% on public offering after rallying in prior sessionMarch 4, 2024 | msn.comQuoin stock soars 60% on FDA update for ichthyosis drugFebruary 22, 2024 | markets.businessinsider.comSalarius Pharmaceuticals Implements Cost-savings MeasuresSee More Headlines Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees2Year Founded2011Profitability EPS (Most Recent Fiscal Year)($21.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-152.20% Return on Assets-111.71% Debt Debt-to-Equity RatioN/A Current Ratio3.91 Quick Ratio3.91 Sales & Book Value Annual Sales$1.84 million Price / Sales1.05 Cash FlowN/A Price / Cash FlowN/A Book Value$10.74 per share Price / Book0.30Miscellaneous Outstanding Shares600,000Free Float564,000Market Cap$1.93 million OptionableNot Optionable Beta0.92 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. David J. Arthur M.B.A. (Age 61)CEO, President & Director Comp: $343.2kMr. Mark J. Rosenblum CPA (Age 71)Executive VP of Finance & CFO Key CompetitorsPhio PharmaceuticalsNASDAQ:PHIOMedAvailNASDAQ:MDVLKazia TherapeuticsNASDAQ:KZIABionomicsNASDAQ:BNOXFSD PharmaNASDAQ:HUGEView All Competitors SLRX Stock Analysis - Frequently Asked Questions How have SLRX shares performed this year? Salarius Pharmaceuticals' stock was trading at $5.20 at the start of the year. Since then, SLRX shares have decreased by 38.7% and is now trading at $3.19. View the best growth stocks for 2024 here. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) posted its earnings results on Monday, May, 13th. The company reported ($3.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($53.60) by $50.32. When did Salarius Pharmaceuticals' stock split? Salarius Pharmaceuticals's stock reverse split on the morning of Monday, June 17th 2024. The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA) and Biocept (BIOC). This page (NASDAQ:SLRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
